morning Good conference to today’s Juan. Thanks, welcome everyone and call.
are what expansion quarter. into this Across We about the including continuing the with all the pending indication the will lies excited our depression this in depression, fronts, our for are for move the bipolar and ahead, treatment results milestone progress year. CAPLYTA ongoing are mark disorder label our with significant potential strong into later pleased PDUFA larger we bipolar schizophrenia approved, treatment development of of in later If a depressive plans for date second beyond results. clinical a this much its major first of CAPLYTA to and market indication our
growth trajectory of lumateperone commercial extensively in brief In million $X.X cover the I'll pipeline, COVID rest also QX we Total CAPLYTA’s of start fall. addition with with in provide our quarter the a reaching we'll first the at to increase in continued total quarter-over-quarter to $XX prescriptions quarter performance, million our late on of highlight same QX, our will the update progress commercial stage last XXXX XX% challenges. $XX $XX.X in revenues where revenues million programs performance compared drove year. a spite update on R&D second period and CAPLYTA’s net in we grew which with continuing in million. in upcoming and our in an Day
this few Neumann the minutes. continued of expect growth details Mark further half Hineline We year. in second and provide in will Larry a
for new of XX, a has sNDAs CAPLYTA, date new and The we're potential the indication action set for drug or accepted bipolar by significant December treatment made for our ahead especially progress CAPLYTA encouraged of the FDA quarter. in supplemental PDUFA the Looking to second XXXX. our applications depression
of medicine to preparing patients. launch be Our would commercial in approved, a promising If team advance an II FDA a and efficacy disorder. disorder. chronic similar lumateperone profile treat suicide cholesterol, with great in population underserved. a fasting placebo highest depression and more milestone a compelling condition CAPLYTA a immediately favorable in serious excellent clinical psychiatric for than approval. with improved for amongst to clinical patients prolactin Bipolar ITCI trials, In changes depressive major XX bipolar CAPLYTA with potential the broad safety I patient bipolar bipolar and a with This EPS, a represent symptoms range new for CAPLYTA product our patients depression or weight, million one total in remains of Results akathisia. for demonstrated is living a approval safely following having are triglycerides, along the glucose, profile. is is large tolerability will the rates important in to with making adults U.S. with progress including of disorders. has bipolar that
We major depressive advanced lumateperone in MDD. have our disorder, or program
Scale, that begin studies XX lumateperone announce to initiated evaluating response from Phase adults Rating the X XX remission. X MDD. pleased versus placebo Montgomery-Åsberg is placebo. inadequate with versus the evaluating in Phase These to the of trials to six MADRS, therapy at shortly. adjunctive blind very second ‘XXX, Study only one MDD, Depression for our an treatment episode million about one-third patients major score milligrams treatment following enrollment for antidepressants week least double baseline endpoint initial Study changed achieving as at ‘XXX, primary or have in treat with anticipated Patient half these enrollment of has are depressive than patient lumateperone trial, total and experienced We More has on global
these in depressive in has patients the of of disorder patients already treatment for CAPLYTA. schizophrenia provide new episodes depression. Lumateperone substantially in We're the to with the shown the of patients. treatment is enthusiastic opportunity about the prospects comorbid possibility of goal this program in to option and needs a bipolar treatment and with major very the expand meet symptoms Our to depressive with efficacy
with half need this this Phase initial for Acting depressive in depression in A many and tolerated results half effective, or Lumateperone disorders of significant during safe Injectable and we're suicide we of ongoing suffer ‘XXX update, year. with respond Study our medicines. episodes. in bipolar X exhibit second a formulation remains Additionally, symptom pharmacokinetics patients typically unmet ‘XXX their illness Study to with exhibit experience complete and severe patients the major who depression, well These comorbidities. of and attempts of one-third risk severity, estimated depressive an features. efforts results second the Long greater higher An expanding antidepressants, mixed We have XXXX. anticipate monotherapy To from in safety anticipate study mixed have patients our ongoing with our poorly lumateperone features these
upon to in upcoming Finally, additional fall. our I'd highlights R&D further will like provide we in which the programs, our on pipeline Day expand
development ITI-XXXX-ODT-SL, our We plan deuterated the program additional We XXXX, for psychosis the of the to behavioral half sublingually. dementia-related ITI-XXXX-ODT-SL studies advancing elderly in are disorders in treatment XXXX. lumateperone. the form This depressive in and second a delivered dementia plan of disturbances initiate and an for tablet is disintegrating of of in orally in certain
neurological you action upcoming potential We the share the initiate on year, inhibitor a in program variety X disease this diseases, cancer. of as design Phase and to X or including cardiovascular a mechanism the therapeutic trial and investigating across we as with focused diseases, trial in PDEX plan will months. phosphodiesterase clinical this details of of well is Parkinson's Our
our Our dyskinesia, which data the symptoms PDEX to and ability study at in presented objective troublesome disease lead describing we QX, for for to program restore preserve inhibitor Research the motor function preclinical with when drug’s In inhibitors Cancer administered to cognition Meeting without the Annual may is modification. effects improve and causing American antitumor conjunction of checkpoint improve Association immunotherapy. neuronal the
human inhibitors to developing evaluating cancers. potential PDEX our models that in are these biomarkers cancer assist treatment are of in currently the data the other We may translation and of
chronic pipeline Lastly, and the models a developed for in shown and acute disorder. pain. ITI-XXX in modulator as use efficacy ITI-XXX disorder opioid a promising is opioid of our new and opioid use and receptors, in asset acts of serotonin as animal treatment both being
dose the single bipolar quarter disorders. portfolio future team half lives of the this will with continued ongoing position of equivalents cash, activities confirm as in $XXX.X depression. this financial during and commitment improve of with growing has and in accomplished this our proud to and commercial year. developing to Mark X in what our I'm the a details million neuropsychiatric plans performance from summary, in our study strength commercial of and our the well and therapeutics schizophrenia ended evaluating We share our time. now commercializing Phase tolerability volunteers healthy safety, neurological in cash of patients long-term as team the second innovative Initial ascending results strong In of study in Our anticipated is underway. and ITI-XXX cash. pharmacokinetics are restricted
Following our Larry details additional QX performance. will his remarks, provide on Mark? financial
